Stem cell boost  by Williams, N.
Magazine
R661
Britain got a lift in its pursuit of
stem cell research last month
with the announcement of the
country’s first cloning of a stem
cell line from human embryonic
cells.
A team at King’s College
London made the
announcement as the high cost
of using cells from the handful
of other cell lines established
around the world since 1998
was increasingly hampering
research. 
Their achievement puts the
UK among a handful of other
countries at the forefront of the
field. It heralds an era of much
cheaper and readily available
stem cells for researchers in the
UK and Europe.
Cells should be available to
researchers later this year when
the King’s College team have
grown sufficient numbers to
deposit some in the UK stem
cell bank, run by the Medical
Research Council.
Stephen Minger, a member of
the group, said they used 58
embryos to generate three
stem-cell populations, but two
were lost at an early stage. But
he said this was fewer embryos
than was used by other groups
and attributed the success to
the use of donated embryos
that had been screened for
genetic disorders, rather than
discarded embryos from in vitro
fertilisation procedures which
may not be of sufficient quality.
The first human embryonic
stem cell lines were created in
1998. There are just nine lines
available across the world, the
majority from Singapore, and
they are extremely expensive.
Scientists at King’s College
were granted one of the first two
licences to produce human
embryonic stem cells by the
Human Fertilisation and
Embryology Authority early last
year.
“Embryonic stem cells are the
most useful ones because they
are very primitive — they have
the potential to develop into any
type of cell in the body. We
have to work out how to coax
them to develop into specific
types of cells,” says Minger.
“We know that cell
replacement therapy is effective
in treating diseases such as
diabetes and Parkinson’s but it
has been very difficult to
produce enough cells to treat
even one patient. An embryonic
stem cell line would enable us
to produce unlimited amounts.”
Holy grail: Stem cells are the target of much research effort and offer promise in
the research and treatment of many diseases and conditions. (Picture: Science
Photo Library.)





What are they? Three protein
complexes, each containing at
least one PDZ protein–protein
interaction domain, are critical
regulators of cell polarity in
animals. Each complex can be
referred to by one of its primary
components: the Par-3 or Baz
complex, including Par-6 and
aPKC; the Crb complex, including
Sdt; and the Scrib complex,
including Dlg. The Lgl protein,
which has activities similar to the
Scrib complex, seems to physically
associate not with the Scrib but
with the Baz complex.
Are they conserved across
species? Yes: orthologous
complexes are found in worms,
flies and vertebrates. Not only is
the composition of the complexes
conserved, but there is also
remarkable conservation of their
localization, particularly in epithelial
cells. Nevertheless, the mutant
phenotypes caused by defects in
components of the complexes vary
across species, suggesting that the
story may be more complicated.
How were they identified?
Primarily through genetic screens in
model organisms. Mutations of Crb,
Sdt and Baz cause polarity defects
in Drosophila embryonic epithelia,
while those of Par-3 and Par-6
disrupt cytoplasmic partitioning in
the early Caenorhabditis elegans
zygote. A mammalian Par-3
homolog physically associates with
aPKC, while Baz is the fly Par-3
homolog. Dlg and Lgl were first
isolated as Drosophila tumor
suppressors that cause overgrowth
and disorganization of imaginal
epithelia. Scrib and its worm
ortholog Let-413 were identified in
screens for epithelial shape defects.
What cells are they active in? All
